Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT07490769

Levetiracetam Three Times Daily in Epilepsy

Led by Waad Alkathiri · Updated on 2026-03-24

120

Participants Needed

1

Research Sites

169 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this clinical trial is to evaluate the efficacy and tolerability of Levetiracetam administered three times daily in patients with epilepsy. The primary objective is to investigate whether orally administered Levetiracetam three times daily dosing is superior in seizure-free days compared to standard twice-daily dosing in patients with epilepsy. Key questions include: * Does LEV improve seizure control, as measured by seizure-free days? * What adverse events or safety concerns are observed with LEV treatment? Participants will receive Levetiracetam administered three times daily during the treatment phase. The study will use a self-matched, pre-post design in which each participant serves as their own control. Baseline seizure activity and safety data will be collected prior to LEV initiation and compared with data obtained during the treatment period. Participants will attend scheduled clinic visits for efficacy and safety evaluations and will maintain a daily diary to record seizure frequency and any treatment-related events.

CONDITIONS

Official Title

Levetiracetam Three Times Daily in Epilepsy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18 years or older
  • Diagnosed with uncontrolled epilepsy of any type with one or more unprovoked seizures in the last 6 months
  • Currently on Levetiracetam monotherapy
  • Have been using Levetiracetam for at least 12 months prior to enrollment
  • Taking high dose Levetiracetam (1.5 to 3 grams daily)
Not Eligible

You will not qualify if you...

  • Younger than 18 years
  • Received intravenous Levetiracetam within the last 24 hours
  • Using other antiepileptic drugs simultaneously
  • Received other antiepileptic drugs in the last two weeks
  • Pregnant women
  • Renal impairment with creatinine clearance less than 30 or acute kidney injury

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

King Saud University

Riyadh, Riyadh Region, Saudi Arabia, 13321

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Levetiracetam Three Times Daily in Epilepsy | DecenTrialz